Key result
The Trifecta GT bioprosthesis was designed with novel antileaflet calcification and anti-support strut distortion technology to mitigate unusually high early structural valve degeneration rates.
This commentary highlights concerns regarding early structural valve degeneration with the Trifecta GT bioprosthesis, suggesting that newer iterations may not always yield improved durability.
Structural valve degeneration (SVD) is a major disadvantage of surgical aortic valve replacement (AVR) with a bioprosthesis. A recent single-center series demonstrated that the Trifecta valve (Abbott Vascular, Santa Clara, Calif) can be safely implanted in the aortic position with excellent hemodynamics and midterm durability,1 whereas others have shown unusually high early SVD rates with this prosthesis.2 The newer-generation Trifecta with Glide Technology (GT) was designed to improve these results, using novel antileaflet calcification and anti-support strut distortion technology.
No takes yet. Share an insight, caveat, or question.
Porterie et al. (2020) conducted an editorial in Structural valve degeneration after surgical aortic valve replacement. Trifecta GT bioprosthesis was evaluated. The Trifecta GT bioprosthesis was designed with novel antileaflet calcification and anti-support strut distortion technology to mitigate unusually high early structural valve degeneration rates.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: